风湿性关节炎患者中甲状腺素不耐受性高患病率:一个横截面研究
Harjit Singh Nalwa1, Tushar Singh Barwal1, Parul Chugh1
1Department of Biotechnology and Research, Sir Ganga Ram Hospital, New Delhi, 110060, India.
BMC rheumatology
|July 21, 2025
概括
在类风湿性关节炎 (RA) 患者中,甲基酸 (MTX) 不耐受是常见的,影响34.5%并且经常引起恶心. 早期检测MTX不耐受性对于有效的RA管理至关重要.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 甲甲酸 (MTX) 是一种用于治疗类风湿性关节炎 (RA) 的主要疾病修饰性抗风湿药物 (DMARD).
- 胃肠道的不良影响限制了MTX在一些RA患者的使用.
- 早期识别MTX不耐受性可以改善治疗坚持和结果.
研究的目的:
- 确定在接受口服治疗的印度RA患者中MTX不耐受性的患病率.
- 为了确定与MTX不耐受相关的风险因素.
主要方法:
- 对200名成人RA患者进行横截面研究,使用口服或皮下MTX≥3个月.
- 评估MTX不耐受性使用甲基不耐受性严重性得分 (MISS) 问卷 (得分≥6).
- 收集人口统计数据,MTX细节和疾病活动 (DAS-28 CRP).
主要成果:
- 在RA患者中,MTX不耐受性患病率为34.5%.
- 恶心 (85.5%) 和腹部不适 (59.42%) 是最常见的症状.
- 多变量分析将MTX不耐受性与女性性别,更高的疾病严重程度和增加的MTX剂量联系起来.
结论:
- 在成人RA患者中存在显著的MTX不耐受性,症状预先和关联性地发生.
- 每周15毫克或更高的MTX剂量可能与不耐受性相关.
- 需要客观的监测,以便在RA中早期检测和管理MTX不耐受.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:11Genome-wide Association Studies-GWAS
14.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
65
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
65
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203